<clinical_study>
<study_id>
<org_name>
  Lilly
</org_name>
<org_full_name>
  Eli Lilly and Company
</org_full_name>
<org_study_id>
  11716
</org_study_id>
<secondary_id>
  B3D-EW-GHDH
</secondary_id>
<nct_id>
  NCT00503399
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis
</textblock>
</brief_title>
<acronym>
  EuroGIOPS
</acronym>
<official_title>
<textblock>
  Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Eli Lilly and Company
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<name_title>
  Chief Medical Officer
</name_title>
<organization>
  Eli Lilly
</organization>
</resp_party>
<oversight_info>
<regulatory_authority>
  Germany: Federal Institute for Drugs and Medical Devices
</regulatory_authority>
<regulatory_authority>
  Greece: National Organization of Medicines
</regulatory_authority>
<regulatory_authority>
  Italy: Ethics Committee
</regulatory_authority>
<regulatory_authority>
  Spain: Spanish Agency of Medicines
</regulatory_authority>
<has_dmc>
  No
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
  The objective of this study is to test the hypothesis that teriparatide is superior to the active comparator in the change from baseline to 18 months of lumbar spine volumetric trabecular bone mineral density in males with glucocorticoid-induced osteoporosis.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
  This study is a multinational, European, multicenter, randomized, open-label, active comparator controlled study with two study periods:  a screening phase of up to 6 weeks, and an open-label treatment phase of 18 months.
  Approximately 100 adult men with osteoporosis associated with sustained glucocorticoid therapy will be enrolled into the study.  Approximately one half of the patients (at all investigational sites) will be randomized to teriparatide 20 micrograms/day (given as a subcutaneous injection), and the other half randomized to risedronate 35 mg once weekly oral tablet.  All patients will receive approximately 1000 mg/day elemental calcium and 800 to 1200 IU/day of vitamin D.
</textblock>
</detailed_descr>
<status_block>
<status>
  Recruiting
</status>
<date>
2008-09 
</date>
</status_block>
<start_date>
<date>
  2007-07
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date
 type="Anticipated"
>
<date>
2010-08 
</date>
</last_follow_up_date>
<primary_compl_date
 type="Anticipated"
>
<date>
  2010-08
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Active Control
</design>
<design>
  Parallel Assignment
</design>
<design>
  Efficacy Study
</design>
<number_of_arms>
  2
</number_of_arms>
<primary_outcome>
<measure>
 Lumbar spine  volumetric  trabecular     bone mineral density (BMD) by  quantitative  computerized  tomography  (QCT)  
</measure>
<time_frame>
  From baseline to 18 months
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
 Lumbar spine volumetric     trabecular BMD by QCT 
</measure>
<time_frame>
At   6    months  
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
 3-D microstructure variables by high-resolution QCT (HR-QCT)in the 12th thoracic vertebra (T12) 
</measure>
<time_frame>
  At baseline, 6 and 18 months
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
 Biomechanical variables by   finite element analysis in the 12 thoracic vertebra 
</measure>
<time_frame>
  At baseline and 18 months
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Areal bone mineral density at lumbar spine, femoral neck, and total hip
</measure>
<time_frame>
  18 months
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Lumbar spine volumetric integral BMD by QCT
</measure>
<time_frame>
  6 months, 18 months
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Serum aminoterminal propeptide of type I procollagen (PINP)
</measure>
<time_frame>
  3, 6, 18 months
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Serum type I collagen degradation fragments
</measure>
<time_frame>
  3, 6, 18 months
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
 Safety 
</measure>
<time_frame>
 Throughout study 
</time_frame>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<enrollment
 type="Anticipated"
>
  104
</enrollment>
<condition>
  Osteoporosis  
</condition>
<arm_group>
<arm_group_label>
A 
</arm_group_label>
<arm_type>
Experimental 
</arm_type>
<description>
<textblock>
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  B
</arm_group_label>
<arm_type>
  Active Comparator
</arm_type>
<description>
<textblock>
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
Teriparatide 
</primary_name>
<description>
<textblock>
  Subcutaneous, 20 micrograms/day, 18 months
</textblock>
</description>
<arm_group_label>
  A
</arm_group_label>
<other_name>
  LY333334
</other_name>
<other_name>
  Forteo
</other_name>
<other_name>
  Forsteo
</other_name>
</intervention>
<intervention>
<intervent_type>
Drug 
</intervent_type>
<primary_name>
 Risedronate 
</primary_name>
<description>
<textblock>
  Oral, 35 mg/week, 18 months
</textblock>
</description>
<arm_group_label>
  B
</arm_group_label>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
 
  - Ambulatory men 25 years of age and older presenting to Visit 1 with a BMD of at least 1.5 SD below the corresponding normal young adult men average BMD (T score of -1.5 or lower), as determined from the manufacturer&apos;s database at any of the following regions of interest:  total hip, femoral neck, or lumbar spine
 
  - Have received glucocorticoid therapy at an average dose of at least 5.0 mg/day of prednisone or its equivalent for a minimum of 3 consecutive months immediately preceding screening (Visit 1), as determined by medical history.  
 
  - A minimum of 2 lumbar vertebrae in the L-1 through L-3 region must be evaluable by quantitative computerized tomography. 
 
  - Normal or clinically insignificant abnormal laboratory values (as determined by the investigator) including serum calcium, PTH(1 84), and 25 hydroxyvitamin D concentrations, and alkaline phosphatase activity.
 
 
  Exclusion Criteria:
 
    - Presence of a mild, moderate or severe spinal fracture in both T-12 and L-1, as determined by the central reading facility using the semiquantitative technique. 
 
  - Abnormal albumin-corrected serum calcium levels
 
  - History of unresolved skeletal diseases that affect bone metabolism other than glucocorticoid-induced osteoporosis
 
  - History of malignant neoplasms in the 5 years prior to Visit 2, with the exception of superficial basal cell or squamous cell carcinomas of the skin that have been definitively treated. Increased baseline risk of osteosarcoma; this includes patients with Paget&apos;s disease of the bone, previous primary skeletal malignancy, or skeletal exposure to therapeutic irradiation.
 
  - Abnormal thyroid function not corrected by therapy
 
  - Past and/or current treatment with certain medications.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Male
</gender>
<minimum_age>
  25 Years
</minimum_age>
<maximum_age>
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
</name>
<affiliation>
<agency>
  Eli Lilly
</agency>
</affiliation>
</investigator>
<contact>
<name>
  There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
</name>
<phone>
  1-317-615-4559
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Frankfurt
</city>
<state>
</state>
<zip>
  60528
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Hamburg
</city>
<state>
</state>
<zip>
  22415
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Heinsberg
</city>
<state>
</state>
<zip>
  52525
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Leverkusen
</city>
<state>
</state>
<zip>
  51375
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Magdeburg
</city>
<state>
</state>
<zip>
  D-39110
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Potsdam
</city>
<state>
</state>
<zip>
  14469
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Bad Nauheim
</city>
<state>
</state>
<zip>
  D-61231
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Kifissia
</city>
<state>
</state>
<zip>
  14561
</zip>
<country>
  Greece
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Thessaloniki
</city>
<state>
</state>
<zip>
  56429
</zip>
<country>
  Greece
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Pisa
</city>
<state>
</state>
<zip>
  56100
</zip>
<country>
  Italy
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Rome
</city>
<state>
</state>
<zip>
  00161
</zip>
<country>
  Italy
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Siena
</city>
<state>
</state>
<zip>
  53100
</zip>
<country>
  Italy
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Barcelona
</city>
<state>
</state>
<zip>
  08907
</zip>
<country>
  Spain
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Madrid
</city>
<state>
</state>
<zip>
  28046
</zip>
<country>
  Spain
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<see_also>
<annotation>
<textblock>
  Lilly Clinical Trial Registry
</textblock>
</annotation>
<url>
  http://www.lillytrials.com
</url>
</see_also>
<keyword>
  Glucocorticoid Induced
</keyword>
<initial_release_date>
  2007-07-16
</initial_release_date>
<last_release_date>
2008-09-10 
</last_release_date>
</clinical_study>
